REPLIMUNE GROUP, INC.
REPL US76029N1063
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.
Annual Performance 1
| 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -29% | -7% | -68% | 40% | 0% |
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
| Person | Price | Shares | Total | Published | Completed |
|---|---|---|---|---|---|
| Hill Emily Luisa CFO |
5.37 USD |
9,154 Sold |
49,157 USD |
15/08/2025 | 15/08/2025 |
| Schwendenman Andrew CCO |
8.05 USD |
3,287 Sold |
26,460 USD |
20/05/2025 | 20/05/2025 |
| Hill Emily Luisa CFO |
8.05 USD |
2,535 Sold |
20,407 USD |
20/05/2025 | 20/05/2025 |
| Sarchi Christopher CCO |
8.05 USD |
3,749 Sold |
30,179 USD |
20/05/2025 | 20/05/2025 |
| Patel Sushil CEO |
8.06 USD |
25,105 Sold |
202,346 USD |
20/05/2025 | 20/05/2025 |
| Astley-sparke Philip O |
8.06 USD |
32,279 Sold |
260,169 USD |
20/05/2025 | 20/05/2025 |
| Xynos Konstantinos CMO |
8.06 USD |
7,952 Sold |
64,093 USD |
20/05/2025 | 20/05/2025 |
| Hill Emily Luisa CFO |
8.05 USD |
2,535 Sold |
20,407 USD |
20/05/2025 | 20/05/2025 |
| Patel Sushil CEO |
12.42 USD |
10,000 Sold |
124,200 USD |
16/12/2024 | 16/12/2024 |
| Xynos Konstantinos CMO |
10.78 USD |
7,246 Sold |
78,112 USD |
18/11/2024 | 18/11/2024 |